How Effective Is the Flu Shot? Real Numbers Explained

Seasonal flu vaccine effectiveness in the United States has ranged from about 10% to 60% over the past two decades, depending on the year, with most seasons landing somewhere between 30% and 50%. Those numbers sound underwhelming compared to, say, the measles vaccine, and they are a genuine source of confusion for people trying to decide whether the shot is worth the trip to the pharmacy. But the headline effectiveness figure measures only one thing, and the picture changes when you look at what the vaccine does against hospitalization, intensive care, and death.

What the Year-to-Year Numbers Actually Look Like

The CDC’s Flu Vaccine Effectiveness Network has tracked how well the flu shot prevents medically attended influenza illness every season since the mid-2000s. The overall effectiveness estimates tell a choppy story. In some seasons the vaccine cut the risk of needing to see a doctor for the flu by more than half. In others, it barely made a dent. A few highlights from the data: 2010–11 saw effectiveness of about 60%, while 2014–15 was a dismal 19%. More recently, 2023–24 came in at 44%, and the preliminary 2024–25 estimate was 56%.{¹

If you average things out across many seasons, somewhere around 40% is a reasonable ballpark for overall effectiveness against lab-confirmed flu illness in outpatient settings. That means a vaccinated person is roughly 40% less likely to wind up at a doctor’s office or urgent care clinic with flu than an unvaccinated person. It does not mean 60% of vaccinated people get the flu. The number describes a relative risk reduction, not a failure rate.

Why the Numbers Swing So Wildly From Year to Year

Flu is not one virus. It is a shifting collection of influenza A and B subtypes, and the dominant strain matters enormously for how well the vaccine works in any given season. Over the decade from 2010 to 2020, the vaccine’s track record against A(H1N1) and influenza B was considerably better than against A(H3N2). H3N2 seasons often dragged overall effectiveness estimates below 40%, and in two of the seven seasons where H3N2-specific estimates were available, the confidence intervals suggested the vaccine provided no statistically significant protection at all.²

Influenza B has generally been easier to vaccinate against. Over four seasons of data from the US Flu VE Network, quadrivalent vaccine effectiveness against influenza B ranged from about 48% to 85%, with higher effectiveness in younger children and against the B/Victoria lineage.³

Vaccine scientists have to pick which strains to include in each year’s formulation months before flu season starts, using predictions about which viruses will circulate. When the match is poor, effectiveness drops. But even a mismatch does not zero out protection entirely. A systematic review and meta-analysis of randomized trials found that both inactivated and live-attenuated flu vaccines retained meaningful, if reduced, effectiveness against mismatched strains. In adults, the inactivated vaccine had about 52% effectiveness against mismatched strains compared to 65% against matched ones.⁴

How Growing Vaccines in Eggs Can Weaken Them

Most flu vaccines worldwide are still grown in chicken eggs. The virus sometimes picks up mutations as it adapts to growing in avian cells, and those mutations can change the parts of the virus that your immune system learns to recognize. The result is a subtle but real mismatch between the vaccine virus and the actual circulating strain, even when the “correct” strain was chosen for the vaccine. This is called egg adaptation, and it has been a persistent headache for H3N2 in particular.⁵

An expert consensus estimated that egg-adaptation mutations reduce vaccine effectiveness by roughly 4–16%, with the biggest hit falling on H3N2 in people under 65.⁶ Which specific mutations emerge depends on the genetic background of the circulating strain, so the severity of the egg-adaptation problem varies from year to year.⁷

Cell-based and recombinant vaccines were developed partly to dodge this issue. In theory, growing the virus in mammalian cells or skipping the virus entirely (as recombinant vaccines do) should eliminate egg-adaptation mutations and produce a better match. In practice, the real-world advantage has been hard to pin down. A study of the 2022–23 season in adults aged 18–64 found that cell-based and egg-based vaccines provided comparable protection against hospitalization.⁸ A randomized trial comparing recombinant to egg-based vaccine in adults found a relative advantage of about 29% for recombinant, but the confidence interval was wide enough to include the possibility of no benefit.⁹ A cluster-randomized trial in nursing homes found nearly identical hospitalization and death rates between recombinant and standard egg-based vaccine groups.¹⁰ The promise of non-egg-based vaccines is real, but the evidence so far has not shown a consistent, dramatic edge in the populations studied.

Protection Against Severe Illness Is the Bigger Story

The headline effectiveness numbers measure protection against any medically attended flu illness, meaning you felt sick enough to go see someone. But most people’s real fear is being hospitalized, landing in intensive care, or dying. Here the vaccine performs better than its outpatient numbers suggest.

During the 2023–24 season, the flu shot was about 58% effective against hospitalization and emergency department visits in children and adolescents, and about 39% effective against hospitalization in adults.¹¹ A large meta-analysis pooling data across many seasons found the vaccine was about 42% effective against flu-related hospitalization, roughly 52% effective at keeping people out of the ICU, and about 55% effective at preventing the need for a ventilator.¹² A Spanish study over six flu seasons found that vaccination was associated with a 23% reduction in the combined risk of ICU admission or death among hospitalized flu patients.¹³

In other words, even in seasons when the vaccine is mediocre at preventing a trip to the doctor, it still meaningfully reduces your chances of ending up in a hospital bed. The protection is not perfect, but it is consistently in the direction of less-severe illness when breakthrough infections happen.

The Flu Shot and Children

Children benefit from the flu vaccine at least as much as adults, and the data on preventing pediatric deaths is particularly striking. An analysis of flu-associated pediatric deaths reported in the United States from 2016 through 2025 found that vaccination was 80% effective at preventing fatal influenza in children aged 6 months to 17 years. Among children without underlying health conditions, the estimate was even higher, at 87%.¹⁴ An earlier analysis covering 2010–2014 found 65% effectiveness against pediatric flu death overall, and 51% in children with high-risk medical conditions.¹⁵

These numbers are substantially higher than the effectiveness against outpatient illness, and they represent an outcome where even partial protection carries enormous weight. A vaccine that is 40% effective at keeping a child from getting the flu at all but 80% effective at preventing death from the flu is doing more than the headline number captures.

Vaccinating During Pregnancy Protects Newborns

Babies under six months are too young to be vaccinated themselves, but they can inherit flu-fighting antibodies from their mothers. A study of pregnant women who received the flu shot found it was about 63% effective at preventing lab-confirmed influenza in their infants, and respiratory illness with fever dropped by roughly 29% among those babies.¹⁶ Another study estimated that maternal vaccination was over 90% effective at preventing flu-related hospitalization in infants under six months.¹⁷

Timing matters. Babies born to mothers vaccinated in the second or third trimester had significantly higher levels of flu-specific antibodies in their cord blood compared to babies born to unvaccinated mothers.¹⁸ Those transferred antibodies serve as a shield during the window when the infant cannot yet build its own vaccine response.

Protection Fades Over the Course of a Season

Flu vaccine immunity is not like a light switch that stays on for exactly six months. Antibody levels tend to peak about a month after vaccination and then decline gradually. A systematic review confirmed this pattern: a rise at one month followed by a drop at six months post-vaccination.¹⁹ Modeling work has estimated that measured vaccine effectiveness drops by a few percentage points per month, with the rate depending on the virus type and how intense the flu season is. For a moderate-intensity season, the decline was estimated at roughly 2% per month for H1N1 and about 1% per month for H3N2 and influenza B.²⁰

This waning is why public health guidance generally recommends getting vaccinated in September or October rather than in August. Getting it too early risks having faded protection by the time flu activity peaks in January or February. Getting it too late risks missing early-season illness. There is no perfect window, but early fall is a reasonable compromise for most people.

Does Getting the Shot Every Year Dull Your Response?

This is one of the more uncomfortable questions in flu vaccinology. A systematic review and meta-analysis found that people vaccinated in consecutive seasons did have somewhat lower protection compared to people vaccinated only in the current season. The drop was most pronounced for H3N2, where consecutive vaccination was associated with about 18 percentage points less effectiveness, and smaller for H1N1 (about 9 points) and influenza B (about 7 points).²¹ However, that same meta-analysis found that vaccination in both seasons still provided better protection than no vaccination at all. Getting the shot annually is still better than skipping years, even if the marginal boost from each successive year may be smaller.

A study of healthcare workers offered a mechanistic window into why this happens: repeated vaccination with the same virus strains increased antibody persistence but dampened the fresh antibody response to subsequent doses. Updating the vaccine viruses appeared to partially restore the response.²² This phenomenon is tangled up with a concept called immunological imprinting: your immune system’s first encounter with a flu virus shapes how it responds to all subsequent flu encounters. Early-life exposure can create a template that biases your immune response toward the strain you first met, sometimes at the expense of responding optimally to newer ones.²³ Some researchers see this as a potential lever: if you could shape that first imprint through vaccination before a child’s first natural infection, you might set up a broader, more durable immune foundation.²⁴

Cardiovascular Benefits Beyond the Lungs

One of the more surprising findings in flu vaccine research is its apparent effect on heart attacks and strokes. A meta-analysis of clinical trials found that flu vaccination was associated with a roughly 30% reduction in major cardiovascular events among people at high risk, with an absolute risk difference meaning that about 58 people needed to be vaccinated to prevent one major event within a year.²⁵ A more recent meta-analysis also found a significant reduction in cardiovascular risk among vaccinated patients.²⁶

In elderly populations, vaccination has been linked to reduced hospitalizations for cardiac disease by about 19% and for stroke by 16–23% across two flu seasons.²⁷ The mechanism is thought to involve the systemic inflammation that a flu infection triggers, which can destabilize arterial plaques and increase clotting risk. Preventing the infection, or at least softening its severity, appears to reduce that cardiovascular cascade.

Herd Protection and the Limits of Individual Data

When enough people in a community are vaccinated, unvaccinated individuals also benefit because the virus has fewer hosts to spread through. Modeling for Germany estimated that vaccinating children aged 2–17 at rates of 20–60% would prevent four to seven times as many cases among unvaccinated people as among the vaccinated children themselves. For outcomes like flu-related death, which disproportionately affect unvaccinated elderly adults, the indirect benefit could exceed the direct benefit by a factor of 20 or more.²⁸

Real-world evidence for this herd effect has been harder to nail down. An eight-year household cohort study in the US found little evidence of indirect protection after adjusting for confounders: unvaccinated people in partly vaccinated households were not significantly less likely to get flu than unvaccinated people in fully unvaccinated households.²⁹ The disconnect between the modeling and the household data likely reflects that current vaccination coverage is too patchy and vaccine effectiveness too variable to generate a strong, measurable herd effect at the household level.

Is the Flu Shot Cost-Effective?

Flu vaccination consistently falls within the range of cost-effectiveness that health systems consider worthwhile. For adults 65 and older, the vaccine is often cost-saving, meaning it prevents enough hospitalizations and medical costs to more than pay for itself. For working-age adults between 18 and 64, estimates ranged from about $8,000 to $39,000 per quality-adjusted life year gained, which compares favorably to other widely accepted preventive measures like breast cancer screening or colorectal cancer screening.³⁰ A separate analysis found that vaccination remained cost-effective for older adults even at vaccine effectiveness estimates as low as 4%.³¹ For younger, healthy adults without risk factors, the economic case is weaker, though workplace absenteeism and productivity losses are harder to capture in formal models.

Nasal Spray Versus the Needle

The live-attenuated nasal spray vaccine works differently from the standard injected shot. The spray delivers a weakened live virus to the lining of the nose, prompting a local immune response, while the injected version uses killed virus to generate a systemic antibody response. In children, the two approaches stimulate distinct immune profiles. The injected vaccine is better at boosting circulating memory immune cells, while the nasal spray generates a mucosal response that the shot does not.³²

A systematic review and meta-analysis comparing the two in children found no overall significant difference in efficacy between the quadrivalent nasal spray and the standard injected vaccine. However, when looking at larger multi-center trials specifically, the trivalent nasal spray was superior to the trivalent injected vaccine in children.³³ For adults, the nasal spray generally performs less well than the injected vaccine, and it is not recommended for people over 50 or those with weakened immune systems.

The Search for a Universal Flu Vaccine

The annual guessing game of which strains to include is the single biggest limitation of current flu vaccines. Several research programs are trying to develop vaccines that target parts of the influenza virus that do not change much from year to year, which would eliminate the need for a new formulation each season. One leading approach uses chimeric constructs that combine unusual head portions of the virus’s surface protein with a conserved stalk region, training the immune system to focus on the stable part rather than the highly variable part. Other candidates target different conserved viral proteins altogether. A phase 2 trial of one such candidate, called FLU-v, found it was immunogenic with adjuvant and was recommended for further development.³⁴ None of these candidates have reached the market yet, and the timeline to a truly universal flu vaccine remains uncertain. But the science is no longer theoretical: multiple approaches are in clinical trials, and the problem of strain-matching could eventually become a thing of the past.